

Carolyn S P Lam

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8092300/carolyn-s-p-lam-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

21,219
citations

75
h-index

135
g-index

473
ext. papers

32,801
ext. citations

8.5
avg, IF

7.03
L-index

#	Paper	IF	Citations
382	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
381	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
380	Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 1119-26	15.1	724
379	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
378	Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2010 , 3, 588-95	7.6	650
377	Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 845-54	15.1	458
376	Epidemiology and clinical course of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2011 , 13, 18-28	12.3	442
375	Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. <i>Circulation</i> , 2007 , 115, 1982-90	16.7	393
374	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019 , 40, 3297-3317	9.5	379
373	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021 , 385, 1451-1461	59.2	358
372	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020 , 382, 1883-1893	59.2	333
371	Age-associated increases in pulmonary artery systolic pressure in the general population. <i>Circulation</i> , 2009 , 119, 2663-70	16.7	314
370	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2281-93	15.1	313
369	Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 410-8	15.1	303
368	Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2628-2639	15.1	263
367	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. <i>European Heart Journal</i> , 2014 , 35, 2797-815	9.5	231
366	Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. <i>Circulation</i> , 2011 , 124, 24-30	16.7	222

365	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9	213
364	Pulmonary pressures and death in heart failure: a community study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 222-31	15.1	200
363	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. <i>European Heart Journal</i> , 2018 , 39, 3439-3450	9.5	195
362	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heArT failure patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017 , 38, 1119-1127	9.5	192
361	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2251-62	27.4	188
360	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. <i>New England Journal of Medicine</i> , 2018 , 379, 1332-1342	59.2	181
359	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 471-482	7.9	176
358	Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. <i>European Journal of Heart Failure</i> , 2016 , 18, 588-98	12.3	173
357	Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2018 , 138, 198-205	16.7	169
356	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017 , 92, 1068-1078	7.1	168
355	Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. <i>Chest</i> , 2014 , 146, 1274-1285	5.3	162
354	Left ventricular function and exercise capacity. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 301, 286-94	27.4	161
353	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	12.3	159
352	Sex differences in heart failure. <i>European Heart Journal</i> , 2019 , 40, 3859-3868c	9.5	159
351	Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2217-2228	15.1	157
350	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018 , 39, 2780-2792	9.5	155
349	Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction. <i>Heart</i> , 2011 , 97, 964-9	5.1	147
348	Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2012 , 14, 1338-47	12.3	143

347	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and	12.3	143
346	How do patients with heart failure with preserved ejection fraction die? <i>European Journal of Heart Failure</i> , 2013 , 15, 604-13	12.3	138
345	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018 , 20, 16-37	12.3	137
344	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	12.3	137
343	Heart failure with preserved ejection fraction: a clinical dilemma. <i>European Heart Journal</i> , 2014 , 35, 1022-32	12.3	136
342	Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001699	11.6	135
341	Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 571-8	7.6	129
340	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2016 , 18, 1472-1487	12.3	128
339	Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1664-1671	12.3	124
338	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015 , 243, 257-9	3.1	123
337	Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. <i>European Heart Journal</i> , 2018 , 39, 1770-1780	9.5	123
336	Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 393-404	12.3	123
335	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
334	Aortic root remodeling over the adult life course: longitudinal data from the Framingham Heart Study. <i>Circulation</i> , 2010 , 122, 884-90	16.7	119
333	Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3242-9	5.6	114
332	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1624-1634	12.3	113
331	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017 , 19, 1390-1400	12.3	111
330	Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1193-202	15.1	106

329	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction: A Nationwide Cohort Study. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	104
328	Influence of sex and hormone status on circulating natriuretic peptides. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 618-26	15.1	98
327	Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e014908	6	97
326	Rationale and design of the SOLuble guanylate Cyclase stimulatOR in heArT failurE Studies (SOCRATES). <i>European Journal of Heart Failure</i> , 2014 , 16, 1026-38	12.3	97
325	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. <i>European Heart Journal</i> , 2016 , 37, 3141-3153	9.5	97
324	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018 , 277, 234-255	3.1	93
323	Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2016 , 18, 81-8	12.3	90
322	Patient selection in heart failure with preserved ejection fraction clinical trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1668-1682	15.1	89
321	Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. <i>European Heart Journal</i> , 2015 , 36, 2050-2060	9.5	89
320	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17058	51.1	87
319	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume. <i>JACC: Heart Failure</i> , 2017 , 5, 92-98	7.9	86
318	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020 , 22, 391-412	12.3	84
317	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	84
316	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019 , 394, 1254-1263	4.0	83
315	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 96-104	7.9	83
314	Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 1303-1311	12.3	83
313	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. <i>Lancet, The</i> , 2021 , 397, 2385-2438	4.0	80
312	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , 2021 , 143, 337-349	16.7	80

311	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021 , 385, 896-907	59.2	79
310	SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. <i>Journal of the American Heart Association</i> , 2019 , 8, e013389	6	78
309	Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. <i>European Journal of Heart Failure</i> , 2018 , 20, 738-747	12.3	76
308	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDRI Research to Practice project. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1637-1645	3.9	73
307	Iron deficiency in a multi-ethnic Asian population with and without heart failure: prevalence, clinical correlates, functional significance and prognosis. <i>European Journal of Heart Failure</i> , 2014 , 16, 1125-32	12.3	72
306	Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 1479-84	9.4	72
305	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 1512-1521	27.4	71
304	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004962	7.6	70
303	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. <i>Journal of Controlled Release</i> , 2017 , 247, 127-133	11.7	69
302	Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. <i>Circulation</i> , 2020 , 141, 540-548	16.7	69
301	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018 , 6, e1008-e1018	13.6	67
300	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019 , 21, 23-36	12.3	64
299	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017 , 38, 2869-2873	9.5	64
298	A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. <i>Human Molecular Genetics</i> , 2011 , 20, 1241-51	5.6	60
297	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018 , 15, e1002541	11.6	60
296	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016 , 22, 1-32	1.7	60
295	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. <i>European Journal of Heart Failure</i> , 2017 , 19, 1651-1660	12.3	59
294	Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model. <i>Hypertension</i> , 2007 , 50, 503-11	8.5	59

293	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 653-662	18.1	58
292	Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". <i>Circulation</i> , 2010 , 122, 370-8	16.7	56
291	Variable phenotype in murine transverse aortic constriction. <i>Cardiovascular Pathology</i> , 2012 , 21, 188-98	3.8	55
290	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	15.1	55
289	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , 2017 , 19, 782-791	12.3	54
288	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 306-317	7.9	54
287	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 425-432	4.1	54
286	Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. <i>European Journal of Heart Failure</i> , 2013 , 15, 928-36	12.3	54
285	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018 , 20, 1664-1672	12.3	54
284	What have we learned about heart failure with mid-range ejection fraction one year after its introduction?. <i>European Journal of Heart Failure</i> , 2017 , 19, 1569-1573	12.3	51
283	Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in Singapore. <i>Cell</i> , 2019 , 179, 736-749.e15	56.2	51
282	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA). <i>ESC European Journal of Heart Failure</i> , 2021 , 23, 1-131	12.3	50
281	Correlation of the New York Heart Association Classification and the 6-Minute Walk Distance: A Systematic Review. <i>Clinical Cardiology</i> , 2015 , 38, 621-8	3.3	49
280	The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design. <i>Journal of Cardiac Failure</i> , 2013 , 19, 156-62	3.3	47
279	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020 , 8, e411-e422	13.6	46
278	The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1638-1647	12.3	46
277	Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1300-1313	15.1	44
276	Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology: A Detailed Invasive Hemodynamic and Echocardiographic Analysis. <i>JACC: Heart Failure</i> , 2019 , 7, 239-249	7.9	44

275	Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. <i>Diabetes and Vascular Disease Research</i> , 2015 , 12, 234-8	3.3	44
274	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017 , 5, 14-24	7.9	42
273	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
272	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1079-1098	6.1	41
271	Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>European Journal of Heart Failure</i> , 2020 , 22, 1551-1567	12.3	41
270	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
269	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 601-612	15.1	40
268	Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2539-2550	15.1	40
267	20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. <i>Lancet Public Health</i> , 2019 , 4, e406-e420	22.4	39
266	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1217-1225	12.3	39
265	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019 , 40, 3593-3602	9.5	38
264	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019 , 8, e013114	6	38
263	The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1577-88	3.8	38
262	Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. <i>American Journal of Cardiology</i> , 2012 , 109, 1494-8	3	38
261	The mitral L wave: a marker of pseudonormal filling and predictor of heart failure in patients with left ventricular hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2005 , 18, 336-41	5.8	38
260	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015 , 17, 301-12	12.3	37
259	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 606-615	18.1	37
258	Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency. <i>European Heart Journal</i> , 2013 , 34, 676-83	9.5	36

257	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2018 , 24, 177-185	3.3	36
256	Aortic root remodeling and risk of heart failure in the Framingham Heart study. <i>JACC: Heart Failure</i> , 2013 , 1, 79-83	7.9	35
255	Bedside assessment of cardiac hemodynamics: the impact of noninvasive testing and examiner experience. <i>American Journal of Medicine</i> , 2011 , 124, 1051-7	2.4	35
254	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1596-1604	12.3	35
253	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. <i>JAMA Cardiology</i> , 2019 , 4, 515-523	16.2	34
252	Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. <i>JACC: Heart Failure</i> , 2016 , 4, 419-27	7.9	34
251	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 1203-1212	9.5	34
250	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018 , 39, 3867-3875	9.5	33
249	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019 , 14, 197-214	2.9	33
248	Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. <i>JACC: Heart Failure</i> , 2016 , 4, 502-509	7.9	32
247	Vascular Health Indices and Cognitive Domain Function: Singapore Longitudinal Ageing Studies. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 27-40	4.3	32
246	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. <i>Circulation</i> , 2020 , 142, 2029-2044	16.7	32
245	Iron deficiency in chronic heart failure: case-based practical guidance. <i>ESC Heart Failure</i> , 2018 , 5, 764-771	3.7	31
244	Heart failure around the world. <i>European Journal of Heart Failure</i> , 2019 , 21, 1187-1196	12.3	31
243	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered Outcomes Measurement Set for Heart Failure Patients. <i>JACC: Heart Failure</i> , 2020 , 8, 212-222	7.9	31
242	Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized C magnetic resonance spectroscopy study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 357-365	6.7	31
241	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. <i>European Journal of Heart Failure</i> , 2015 , 17, 527-33	12.3	30
240	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. <i>JACC: Heart Failure</i> , 2020 , 8, 931-939	7.9	30

239	Atrial fibrillation modifies the association between pulmonary artery wedge pressure and left ventricular end-diastolic pressure. <i>European Journal of Heart Failure</i> , 2017 , 19, 1483-1490	12.3	29
238	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018 , 138, 2763-2773	16.7	29
237	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 472-485	12.3	28
236	Fussing Over the Middle Child: Heart Failure With Mid-Range Ejection Fraction. <i>Circulation</i> , 2017 , 135, 1279-1280	16.7	27
235	Light to Moderate Habitual Alcohol Consumption Is Associated with Subclinical Ventricular and Left Atrial Mechanical Dysfunction in an Asymptomatic Population: Dose-Response and Propensity Analysis. <i>Journal of the American Society of Echocardiography</i> , 2016 , 29, 1043-1051.e4	5.8	27
234	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 633-640	5.9	27
233	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. <i>PLoS Medicine</i> , 2019 , 16, e1002916	11.6	26
232	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 715-722	12.3	26
231	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. <i>Circulation</i> , 2020 , 141, 4-6	16.7	26
230	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021 , 117, 2108-2124	9.9	26
229	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25
228	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019 , 42, 1792-1799	14.6	25
227	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
226	Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 898-901	12.3	25
225	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. <i>JACC: Heart Failure</i> , 2017 , 5, 157-165	7.9	24
224	Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity. <i>Hypertension</i> , 2010 , 55, 1143-9	8.5	24
223	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1644-1656	15.1	23
222	Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China. <i>Circulation</i> , 2020 , 141, 530-539	16.7	23

221	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017 , 191, 75-81	4.9	23
220	Heart failure with preserved ejection fraction in hypertension. <i>Current Opinion in Cardiology</i> , 2016 , 31, 410-6	2.1	23
219	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019 , 12, e005998	7.6	22
218	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 321-332	7.9	22
217	Natriuretic peptide receptor 3 (NPR3) is regulated by microRNA-100. <i>Journal of Molecular and Cellular Cardiology</i> , 2015 , 82, 13-21	5.8	22
216	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020 , 22, 1147-1155	12.3	22
215	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2020 , 9, e012199	6.1	22
214	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 297-307	12.3	22
213	Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort. <i>PLoS ONE</i> , 2016 , 11, e0148073	3.7	21
212	Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. <i>Circulation</i> , 2020 , 141, 1915-1926	16.7	20
211	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. <i>European Heart Journal</i> , 2020 , 41, 1357-1364	9.5	20
210	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 401-410	16.2	20
209	Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 1281-1289	12.3	20
208	Understanding Contemporary Use of Thiazolidinediones. <i>Circulation: Heart Failure</i> , 2019 , 12, e005855	7.6	19
207	Risk Factors for Heart Failure: 20-Year Population-Based Trends by Sex, Socioeconomic Status, and Ethnicity. <i>Circulation: Heart Failure</i> , 2020 , 13, e006472	7.6	19
206	Coronary sarcoidosis presenting as acute coronary syndrome. <i>Clinical Cardiology</i> , 2009 , 32, E68-71	3.3	19
205	Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community. <i>European Journal of Heart Failure</i> , 2017 , 19, 348-356	12.3	18
204	The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. <i>Journal of Hypertension</i> , 2011 , 29, 1829-36	1.9	18

203	Chronic Rejection of Cardiac Allografts Is Associated With Increased Lymphatic Flow and Cellular Trafficking. <i>Circulation</i> , 2018 , 137, 488-503	16.7	18
202	Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e004540	7.6	18
201	Particulate air pollution on cardiovascular mortality in the tropics: impact on the elderly. <i>Environmental Health</i> , 2019 , 18, 34	6	17
200	Toll-like receptor 7 deficiency promotes survival and reduces adverse left ventricular remodelling after myocardial infarction. <i>Cardiovascular Research</i> , 2019 , 115, 1791-1803	9.9	17
199	Left atrial strain as sensitive marker of left ventricular diastolic dysfunction in heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1956-1965	3.7	17
198	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , 2020 , 22, 1065-1075	12.3	17
197	Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2017 , 19,	6.3	17
196	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10,	5.8	17
195	Effect of Monocyte-to-Lymphocyte Ratio on Heart Failure Characteristics and Hospitalizations in a Coronary Angiography Cohort. <i>American Journal of Cardiology</i> , 2017 , 120, 911-916	3	17
194	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 142-152	15.1	17
193	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020 , 109, 331-338	6.1	17
192	Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2018 , 5, 570-578	3.7	16
191	Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. <i>Scientific Reports</i> , 2017 , 7, 9193	4.9	16
190	A porcine model of heart failure with preserved ejection fraction: magnetic resonance imaging and metabolic energetics. <i>ESC Heart Failure</i> , 2020 , 7, 92-102	3.7	16
189	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 983-991	12.3	16
188	A call to action for new global approaches to cardiovascular disease drug solutions. <i>European Heart Journal</i> , 2021 , 42, 1464-1475	9.5	16
187	High-Sensitivity Sandwich ELISA for Plasma NT-proUcn2: Plasma Concentrations and Relationship to Mortality in Heart Failure. <i>Clinical Chemistry</i> , 2016 , 62, 856-65	5.5	16
186	Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2015 , 17, 135-43	12.3	15

185	Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. <i>Journal of Cardiac Failure</i> , 2017 , 23, 63-71	3.3	15
184	Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. <i>Circulation: Cardiovascular Genetics</i> , 2010 , 3, 492-8		15
183	Revisiting methods for assessing and comparing left ventricular diastolic stiffness: impact of relaxation, external forces, hypertrophy, and comparators. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 293, H2738-46	5.2	15
182	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020 , 22, 2078-2088	12.3	15
181	Assessing the evidence-practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2020 , 22, 646-660	12.3	15
180	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1313-1321	12.3	15
179	Racial Differences in Electrocardiographic Characteristics and Prognostic Significance in Whites Versus Asians. <i>Journal of the American Heart Association</i> , 2016 , 5, e002956	6	15
178	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). <i>American Heart Journal</i> , 2018 , 203, 25-29	4.9	15
177	Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models. <i>European Heart Journal</i> , 2021 , 42, 4420-4430	9.5	15
176	Ethnic differences in atrial fibrillation in patients with heart failure from Asia-Pacific. <i>Heart</i> , 2019 , 105, 842-847	5.1	14
175	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. <i>European Journal of Heart Failure</i> , 2020 , 22, 1472-1482	12.3	14
174	Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). <i>ESC Heart Failure</i> , 2018 , 5, 344-353	3.7	14
173	Cardiac Structural Remodeling, Longitudinal Systolic Strain, and Torsional Mechanics in Lean and Nonlean Dysglycemic Chinese Adults. <i>Circulation: Cardiovascular Imaging</i> , 2018 , 11, e007047	3.9	14
172	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	14
171	A Systematic Review and Network-Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021 ,	7.9	14
170	Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2960-2972	15.1	14
169	Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2019 , 4, 924-937	8.7	14
168	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	13

167	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 834-844	12.3	13
166	Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2353-2355	9.5	13
165	LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy. Findings from the METEOR trial. <i>International Journal of Cardiology</i> , 2018 , 271, 247-253	3.2	13
164	Influenza-Associated Hospitalizations for Cardiovascular Diseases in the Tropics. <i>American Journal of Epidemiology</i> , 2017 , 186, 202-209	3.8	13
163	The socioeconomics of hypertension: how \$50 000 may buy a drop in blood pressure. <i>Hypertension</i> , 2011 , 58, 140-1	8.5	13
162	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1300-1312	12.3	13
161	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 3741-3752	9.5	13
160	Asia-Pacific consensus statement on the optimal use of high-sensitivity troponin assays in acute coronary syndromes diagnosis: focus on hs-TnI. <i>Heart Asia</i> , 2017 , 9, 81-87	1.9	12
159	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020 , 8, 234-242	7.9	12
158	Statin associated lower cancer risk and related mortality in patients with heart failure. <i>European Heart Journal</i> , 2021 , 42, 3049-3059	9.5	12
157	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. <i>JAMA Cardiology</i> , 2021 , 6, 706-712	16.2	12
156	Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020 , 142, 1770-1780	16.7	11
155	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 821-833	12.3	11
154	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2019 , 65, 1221-1227	5.5	11
153	Application of the H FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1288-1291	12.3	11
152	Chronic Indwelling Pleural Catheters Reduce Hospitalizations in Advanced Heart Failure with Refractory Pleural Effusions. <i>Journal of Cardiac Failure</i> , 2009 , 15, S105	3.3	11
151	Age dependent associations of risk factors with heart failure: pooled population based cohort study. <i>BMJ, The</i> , 2021 , 372, n461	5.9	11
150	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. <i>Heart</i> , 2016 , 102, 1464-71	5.1	11

149	Differences in Presentation, Management and Outcomes in Women and Men Presenting to an Emergency Department With Possible Cardiac Chest Pain. <i>Heart Lung and Circulation</i> , 2017 , 26, 1282-1290	1.8	10
148	Obesity-Related Changes in Cardiac Structure and Function Among Asian Men and Women. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2876-2878	15.1	10
147	A Population-wide study of electrocardiographic (ECG) norms and the effect of demographic and anthropometric factors on selected ECG characteristics in young, Southeast Asian males-results from the Singapore Armed Forces ECG (SAFE) study. <i>Annals of Noninvasive Electrocardiology</i> , 2019 , 24, e12634	1.5	10
146	Evaluation of high-sensitivity C-reactive protein and uric acid in vericigat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1675-1683	12.3	10
145	Gender-differences in the associations between circulating creatine kinase, blood pressure, body mass and non-alcoholic fatty liver disease in asymptomatic asians. <i>PLoS ONE</i> , 2017 , 12, e0179898	3.7	10
144	Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review. <i>International Journal of Cardiology</i> , 2018 , 263, 88-93	3.2	10
143	Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial). <i>American Journal of Cardiology</i> , 2019 , 124, 1912-1917	3	10
142	Breakthrough in heart failure with preserved ejection fraction: are we there yet?. <i>Korean Journal of Internal Medicine</i> , 2016 , 31, 1-14	2.5	10
141	The Upcoming Epidemic of Heart Failure in South Asia. <i>Circulation: Heart Failure</i> , 2020 , 13, e007218	7.6	10
140	Association of Age, Sex, Body Size and Ethnicity with Electrocardiographic Values in Community-based Older Asian Adults. <i>Heart Lung and Circulation</i> , 2016 , 25, 705-11	1.8	10
139	Paradoxical Low-Gradient Aortic Stenosis: The HFpEF of Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2447-2448	15.1	10
138	Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	9
137	Prediction of Survival in Asian Patients Hospitalized With Heart Failure: Validation of the OPTIMIZE-HF Risk Score. <i>Journal of Cardiac Failure</i> , 2019 , 25, 571-575	3.3	9
136	Impact of the joint association between sex, age and diabetes on long-term mortality after acute myocardial infarction. <i>BMC Public Health</i> , 2015 , 15, 308	4.1	9
135	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018 , 254, 203-209	3.2	9
134	The mitral annular middiastolic velocity curve: functional correlates and clinical significance in patients with left ventricular hypertrophy. <i>Journal of the American Society of Echocardiography</i> , 2008 , 21, 165-70	5.8	9
133	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020 , 26, 1016-1021	3.3	9
132	Qishen Yiqi dripping pills for chronic ischaemic heart failure: results of the CACT-IHF randomized clinical trial. <i>ESC Heart Failure</i> , 2020 , 7, 3881	3.7	9

131	Epicardial fat in heart failure with reduced versus preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 835-838	12.3	9
130	Defining a 'frequent admitter' phenotype among patients with repeat heart failure admissions. <i>European Journal of Heart Failure</i> , 2019 , 21, 311-318	12.3	9
129	Heart failure with preserved ejection fraction diagnostic scores in an Asian population. <i>European Journal of Heart Failure</i> , 2020 , 22, 1737-1739	12.3	8
128	Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. <i>The Lancet Digital Health</i> , 2021 ,	14.4	8
127	Victims of Success in Failure. <i>Circulation</i> , 2020 , 142, 1129-1131	16.7	8
126	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. <i>Scientific Reports</i> , 2021 , 11, 4885	4.9	8
125	Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 3217-3225	15.1	8
124	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. <i>Circulation</i> , 2021 , 144, 159-169	16.7	8
123	Influence of Ethnicity, Age, and Time on Sex Disparities in Long-Term Cause-Specific Mortality After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	8
122	Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 318-323	6.7	8
121	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. <i>JACC: Heart Failure</i> , 2020 , 8, 359-368	7.9	7
120	Chronic obstructive pulmonary disease and beta-blocker treatment in Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018 , 5, 297-305	3.7	7
119	Impact of aortic root size on left ventricular afterload and stroke volume. <i>European Journal of Applied Physiology</i> , 2016 , 116, 1355-65	3.4	7
118	Comparison of health state values derived from patients and individuals from the general population. <i>Quality of Life Research</i> , 2017 , 26, 3353-3363	3.7	7
117	Teaching cardiac auscultation without patient contact. <i>Medical Education</i> , 2004 , 38, 1184-5	3.7	7
116	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022 , 24, 143-168	12.3	7
115	Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2021 ,	16.7	7
114	Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF). <i>ESC Heart Failure</i> , 2016 , 3, 71-76	3.7	7

113	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , 2018 , 121, 621-627	3	7
112	High-sensitivity troponin I for cardiovascular risk stratification in the general asymptomatic population: Perspectives from Asia-Pacific. <i>International Journal of Cardiology</i> , 2019 , 282, 93-98	3.2	6
111	The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. <i>International Journal of Cardiology</i> , 2020 , 318, 126-129	3.2	6
110	Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review. <i>European Journal of Heart Failure</i> , 2020 , 22, 1586-1597	12.3	6
109	The women's heart health programme: a pilot trial of sex-specific cardiovascular management. <i>BMC Womens Health</i> , 2018 , 18, 56	2.9	6
108	Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 261-266	6.7	6
107	Membrane Proteomics of Impaired Energetics and Cytoskeletal Disorganization in Elderly Diet-Induced Diabetic Mice. <i>Journal of Proteome Research</i> , 2017 , 16, 3504-3513	5.6	6
106	Longitudinal Community-Based Study of QT Interval and Mortality in Southeast Asians. <i>PLoS ONE</i> , 2016 , 11, e0154901	3.7	6
105	Extracellular vesicle Cystatin C and CD14 are associated with both renal dysfunction and heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 2240-2249	3.7	6
104	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 4442-4451	9.5	6
103	Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). <i>BMC Cardiovascular Disorders</i> , 2019 , 19, 259	2.3	6
102	Singapore's health-care system: key features, challenges, and shifts. <i>Lancet, The</i> , 2021 , 398, 1091-1104	40	6
101	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.. <i>Circulation</i> , 2022 , 145, 693-712	16.7	6
100	Cornell product is an ECG marker of heart failure with preserved ejection fraction. <i>Heart Asia</i> , 2019 , 11, e011108	1.9	5
99	Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. <i>European Journal of Heart Failure</i> , 2019 , 21, 685-688	12.3	5
98	Circulating neuregulin1- μ n heart failure with preserved and reduced left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020 , 7, 445-455	3.7	5
97	Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study. <i>ESC Heart Failure</i> , 2020 , 7, 996-1006	3.7	5
96	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 648-656	12.3	5

95	Remote monitoring and digital health tools in CVD management. <i>Nature Reviews Cardiology</i> , 2021 , 18, 457-458	14.8	5
94	Generalizability of HFA-PEFF and HFPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. <i>Journal of Cardiac Failure</i> , 2021 , 27, 756-765	3.3	5
93	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021 , 144, 1489-1499	16.7	5
92	Electrocardiographic Criteria for Left Ventricular Hypertrophy in Asians Differs from Criteria Derived from Western Populations--Community-based Data from an Asian Population. <i>Annals of the Academy of Medicine, Singapore</i> , 2015 , 44, 274-83	2.8	5
91	Cognitive impairment in Asian patients with heart failure: prevalence, biomarkers, clinical correlates, and outcomes. <i>European Journal of Heart Failure</i> , 2019 , 21, 688-690	12.3	4
90	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020 , 7, 1419-1429	3.7	4
89	Ethnic differences in quality of life and its association with survival in patients with heart failure. <i>Clinical Cardiology</i> , 2020 , 43, 976-985	3.3	4
88	N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018 , 5, 279-287	3.7	4
87	Renal Function and Exercise Training in Ambulatory Heart Failure Patients With a Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2018 , 122, 999-1007	3	4
86	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019 , 140, 1359-1361	16.7	4
85	What is normal in HFNEF?: The case for HFpEF. <i>JACC: Heart Failure</i> , 2014 , 2, 541-3	7.9	4
84	Impact Of Sex On Clinical Characteristics And In-Hospital Outcomes In A Multi-Ethnic Southeast Asian Population Of Patients Hospitalized For Acute Heart Failure. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014 , 22, 8	0	4
83	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. <i>European Journal of Heart Failure</i> , 2017 , 19, 1732-1735	12.3	4
82	Management of Cardiovascular Disease Patients With Confirmed or Suspected COVID-19 in Limited Resource Settings. <i>Global Heart</i> , 2020 , 15, 44	2.9	4
81	Drug Layering in Heart Failure: Phenotype-Guided Initiation. <i>JACC: Heart Failure</i> , 2021 , 9, 775-783	7.9	4
80	Impact of Geographic Region on the COMMANDER-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 201-211	7.9	4
79	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1554-1563	6.1	4
78	Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1431-1435	6.7	4

77	The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. <i>Journal of the Chinese Medical Association</i> , 2019 , 82, 447-451	2.8	4
76	An East-West comparison of self-care barriers in heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 615-622	4.3	4
75	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. <i>EClinicalMedicine</i> , 2021 , 32, 100739	11.3	4
74	the Efficacy, Safety, and Tolerability of Additional Serelaxin Administration to Standard Therapy in Asian Patients with Acute Heart Failure: The RELAX-AHF-ASIA trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 812	3.3	4
73	Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. <i>ESC Heart Failure</i> , 2021 ,	3.7	4
72	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 184-197	7.9	4
71	The diabetes-atrial fibrillation paradox. <i>Heart</i> , 2019 , 105, 893	5.1	3
70	Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487319899618	3.9	3
69	Women and Heart Failure: An Emerging Venus-Mars Concept. <i>Current Cardiovascular Risk Reports</i> , 2013 , 7, 212-216	0.9	3
68	Medical Podcasting and : Why, How, and What Now. <i>Circulation</i> , 2017 , 136, 513-515	16.7	3
67	Diabetes and prediabetes in patients with heart failure and preserved ejection fraction.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
66	The Relationship among Carotid Artery Remodeling, Cardiac Geometry, and Serum N-Terminal Pro-B-Type Natriuretic Peptide Level in Asymptomatic Asians: Sex-Differences and Longitudinal GEE Study. <i>PLoS ONE</i> , 2015 , 10, e0131440	3.7	3
65	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2021 ,	18.1	3
64	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1587-1598	15.1	3
63	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 519-527	12.3	3
62	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 754-758	12.3	3
61	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e006962	5.8	3
60	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. <i>Cardiovascular Diabetology</i> , 2021 , 20, 159	8.7	3

59	Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure. <i>Clinical Chemistry</i> , 2021 , 67, 216-226	5.5	3
58	The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease. <i>Global Heart</i> , 2021 , 16, 22	2.9	3
57	Clinical correlates and pharmacological management of Asian patients with concomitant diabetes mellitus and heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 461-468	5	2
56	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 1035-1039	3.2	2
55	Physicians' Perception of the Patient Care Pathway for Acute Heart Failure in Asian Countries: Implications for Resource Allocation, Preventive Strategies and Clinical Trial Design. <i>ASEAN Heart Journal: Official Journal of the ASEAN Federation of Cardiology</i> , 2014 , 22,	0	2
54	Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. <i>Journal of Hypertension</i> , 2014 , 32, 174-80	1.9	2
53	Response to Letter Regarding Article, Cardiac Structure and Ventricular Vascular Function in Persons With Heart Failure and Preserved Ejection Fraction From Olmsted County, Minnesota. <i>Circulation</i> , 2007 , 116,	16.7	2
52	Left atrial structure and function in heart failure with reduced (HFrEF) versus preserved ejection fraction (HFpEF): systematic review and meta-analysis.. <i>Heart Failure Reviews</i> , 2022 , 1	5	2
51	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e021094	6	2
50	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008594	7.6	2
49	Cardiac and renal biomarkers in recreational runners following a 21 km treadmill run. <i>Clinical Cardiology</i> , 2020 , 43, 1443-1449	3.3	2
48	Patient-reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. <i>ESC Heart Failure</i> , 2020 , 7, 2051-2062	3.7	2
47	Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans. <i>Clinical Cardiology</i> , 2021 , 44, 646-655	3.3	2
46	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e007901	7.6	2
45	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	2
44	Impact of stock market volatility on mortality and cardiovascular events. <i>International Journal of Cardiology</i> , 2016 , 223, 318-319	3.2	2
43	Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes. <i>European Journal of Heart Failure</i> , 2018 , 20, 821-822	12.3	2
42	A global perspective of racial differences and outcomes in patients presenting with acute heart failure. <i>American Heart Journal</i> , 2022 , 243, 11-14	4.9	2

41	Tissue factor cytoplasmic domain exacerbates post-infarct left ventricular remodeling via orchestrating cardiac inflammation and angiogenesis. <i>Theranostics</i> , 2021 , 11, 9243-9261	12.1	2
40	Pro-Inflammatory Derangement of the Immuno-Interactome in Heart Failure.. <i>Frontiers in Immunology</i> , 2022 , 13, 817514	8.4	2
39	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19.. <i>Heart</i> , 2021 ,	5.1	2
38	Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019 , 123, 1935-1940	3	1
37	Nitrates in combination with hydralazine in cardiorenal syndrome: a randomized controlled proof-of-concept study. <i>ESC Heart Failure</i> , 2020 , 7, 4267	3.7	1
36	Random Plasma Glucose Levels and Cardiovascular Risk. <i>JAMA Cardiology</i> , 2016 , 1, 823-824	16.2	1
35	Comments on "The impact of SARS on medical house staff ...". <i>Journal of General Internal Medicine</i> , 2005 , 20, 973	4	1
34	Regional Differences in Precipitating Factors of Hospitalization for Acute Heart Failure: Insights from the REPORT-HF Registry.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
33	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 751-754	12.3	1
32	A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy. <i>Communications Biology</i> , 2020 , 3, 697	6.7	1
31	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2021 , 10, e017932	6	1
30	Machine learning versus classical electrocardiographic criteria for echocardiographic left ventricular hypertrophy in a pre-participation cohort. <i>Kardiologia Polska</i> , 2021 , 79, 654-661	0.9	1
29	Methods and rationale of the DISCOVER CKD global observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1570-1578	4.5	1
28	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure: REPORT-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 349-359	7.9	1
27	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1477-1484	12.3	1
26	Associations of obesity and malnutrition with cardiac remodeling and cardiovascular outcomes in Asian adults: A cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003661	11.6	1
25	Subclinical vasculopathy and skeletal muscle metrics in the singapore longitudinal ageing study. <i>Aging</i> , 2021 , 13, 14768-14784	5.6	1
24	Guideline-Directed Medical Therapy in Females with Heart Failure with Reduced Ejection Fraction. <i>Current Heart Failure Reports</i> , 2021 , 18, 284-289	2.8	1

23	Discussion forum response to Canepa et al. <i>European Heart Journal</i> , 2019 , 40, 705-706	9.5	1
22	QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. <i>Cardiology Journal</i> , 2021 , 28, 166-169	1.4	1
21	NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. <i>JACC: Heart Failure</i> , 2021 , 9, 653-663	7.9	1
20	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
19	Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure. <i>JACC Asia</i> , 2021 , 1, 303-313		1
18	Choosing a Career in Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e006026	7.6	0
17	Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort.. <i>Advances in Therapy</i> , 2022 , 39, 1432	4.1	0
16	Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.. <i>Value in Health</i> , 2022 , 25, 451-460	3.3	0
15	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.. <i>JACC: Heart Failure</i> , 2022 , 10, 1-11	7.9	0
14	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e021414	6	0
13	Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world insights of treatment patterns and its relationship with cardiovascular, renal, and metabolic multimorbidities. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 108077	3.2	0
12	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1456-1461	3.3	0
11	Heart failure or heart success?. <i>Cardiovascular Research</i> , 2021 , 117, e29-e34	9.9	0
10	How to Incorporate Sex and Gender Into the Design of Cardiovascular Clinical Trials.. <i>Circulation</i> , 2022 , 145, 499-501	16.7	0
9	Heart Failure Subtypes and Cardiomyopathies in Women.. <i>Circulation Research</i> , 2022 , 130, 436-454	15.7	0
8	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	7.9	0
7	Temporal trends and patterns of infective endocarditis in a Chinese population: A territory-wide study in Hong Kong (2002-2019).. <i>The Lancet Regional Health - Western Pacific</i> , 2022 , 22, 100417	5	0
6	Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 857360	5.4	0

5	Association of Female Menopause With Atrioventricular Mechanics and Outcomes.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 804336	5.4	○
4	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis. <i>ESC Heart Failure</i> ,	3.7	○
3	Reply in response to 'Defining a "frequent admitter" phenotype among patients with repeat heart failure admissions'. <i>European Journal of Heart Failure</i> , 2020 , 22, 385-386	12.3	
2	Scientists on the Spot: A fraction of wisdom on heart failure. <i>Cardiovascular Research</i> , 2021 , 117, e114-e115	11.5	
1	Concomitant Hepatorenal Dysfunction and Malnutrition in Valvular Heart Surgery: Long-Term Prognostic Implications for Death and Heart Failure.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024060	6	